Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. www.cri-report.com - In China, ophthalmic diseases mainly include cataract, glaucoma, ocular inflammations, ...
Please provide your email address to receive an email when new articles are posted on . NASHVILLE, Tenn. — A preservative-free brimonidine tartrate ophthalmic solution was statistically noninferior to ...
FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule ...
Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants ...
Patients may be subject to a variety of different topical medications when undergoing treatment for ocular disease. Preservatives are added to multidose medication bottles to inhibit microbial ...
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies ...
To investigate the long-term results of 3% diquafosol ophthalmic solution as an alternative therapy to existing ophthalmic solutions, including topical immunosuppression, for the treatment of dry eye ...
Opus Genetics, Inc. announced positive results from its Phase 3 clinical trial, LYNX-2, which evaluated Phentolamine Ophthalmic Solution 0.75% for treating chronic night driving impairment in ...
Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for treating presbyopia, achieving its primary and key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results